Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3549492 in Obese or Overweight Participants With Type 2 Diabetes
NCT07030868Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of naperiglipron in obesity, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jun 2025; status: terminated.
02
Drugs
naperiglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07030868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030868.